Study of Ketamine Administered Intravenously and by Sublingual Wafer
Brief Summary
To determine the rate and extent of of absorption of racemic ketamine from sublingual wafer
Study Design
| Study type: | Observational |
|---|---|
| Status: | Completed |
| Study results: | No Results Available |
| Age: | 18 Years to 65 Years (Adult, Older Adult) |
| Enrollment: | 8 () |
| Funded by: | Other |
Masking |
|
Clinical Trial Dates
| Start date: | Jun 11, 2020 | |
|---|---|---|
| Primary Completion: | Jun 11, 2020 | |
| Completion Date: | Jun 11, 2020 | |
| Study First Posted: | Jun 21, 2011 | |
| Results First Posted: | Aug 31, 2020 | |
| Last Updated: | Mar 10, 2015 |
Sponsors / Collaborators
Lead Sponsor:
N/A
Responsible Party:
N/A
Location
- To determine the apparent rate of disintegration of the sublingual wafer
- To determine the overall clinical tolerability of ketamine when administered as a single dose via the sublingual route. Tolerability will be assessed using a range of objective and subjective parameters as assessed using modified Likert and Bond and Lader scales.
Eligibility Criteria
| Sex: | Male |
|---|---|
| Minimum Age: | 18 |
| Maximum Age: | 65 |
More Details
| NCT Number: | NCT01377831 |
|---|---|
| Other IDs: | KET001 |
| Study URL: | https://ClinicalTrials.gov/show/NCT01377831 |
Last updated: Feb 22, 2021